Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 16, 2010; 75 (20) Articles

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

T. Tokuda, M.M. Qureshi, M.T. Ardah, S. Varghese, S.A.S. Shehab, T. Kasai, N. Ishigami, A. Tamaoka, M. Nakagawa, O.M.A. El-Agnaf
First published October 20, 2010, DOI: https://doi.org/10.1212/WNL.0b013e3181fd613b
T. Tokuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.M. Qureshi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.T. Ardah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Varghese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.A.S. Shehab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Kasai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Ishigami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Tamaoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Nakagawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O.M.A. El-Agnaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda, M.M. Qureshi, M.T. Ardah, S. Varghese, S.A.S. Shehab, T. Kasai, N. Ishigami, A. Tamaoka, M. Nakagawa, O.M.A. El-Agnaf
Neurology Nov 2010, 75 (20) 1766-1770; DOI: 10.1212/WNL.0b013e3181fd613b

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
954

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Background: To date, there is no accepted clinical diagnostic test for Parkinson disease (PD) that is based on biochemical analysis of blood or CSF. The discovery of mutations in the SNCA gene encoding α-synuclein in familial parkinsonism and the accumulation of α-synuclein in the PD brain suggested a critical role for this protein in PD etiology.

Methods: We investigated total and α-synuclein oligomers levels in CSF from patients clinically diagnosed with PD, progressive supranuclear palsy (PSP), or Alzheimer disease (AD), and age-matched controls, using ELISA developed in our laboratory.

Results: The levels of α-synuclein oligomers and oligomers/total-α-synuclein ratio in CSF were higher in the PD group (n = 32; p < 0.0001, Mann-Whitney U test) compared to the control group (n = 28). The area under the receiver operating characteristic curve (AUC) indicated a sensitivity of 75.0% and a specificity of 87.5%, with an AUC of 0.859 for increased CSF α-synuclein oligomers in clinically diagnosed PD cases. However, when the CSF oligomers/total-α-synuclein ratio was analyzed, it provided an even greater sensitivity of 89.3% and specificity of 90.6%, with an AUC of 0.948. In another cross-sectional pilot study, we confirmed that the levels of CSF α-synuclein oligomers were higher in patients with PD (n = 25) compared to patients with PSP (n = 18; p < 0.05) or AD (n = 35; p < 0.001) or control subjects (n = 43; p < 0.05).

Conclusion: Our results demonstrate that levels of α-synuclein oligomers in CSF and the oligomers/total-α-synuclein ratio can be useful biomarkers for diagnosis and early detection of PD.

Footnotes

  • Study funding: The laboratory of O.M.E. is supported by the Michael J. Fox Foundation for Parkinson's Research.

  • AD
    Alzheimer disease
    AUC
    area under the receiver operating characteristic curve
    DC
    disease control
    DLB
    dementia with Lewy bodies
    DSM-IV
    Diagnostic and Statistical Manual of Mental Disorders, 4th edition
    HRP
    horseradish peroxidase
    LB
    Lewy body
    mAb
    monoclonal antibody
    NC
    normal control
    PBS
    phosphate-buffered saline
    PBST
    PBS containing 0.05% Tween 20
    PD
    Parkinson disease
    PSP
    progressive supranuclear palsy
    RLU
    relative luminescence units
    ROC
    receiver operating characteristic.

  • Editorial, page 1760

  • Supplemental data at www.neurology.org

  • Received September 1, 2009.
  • Accepted May 25, 2010.
  • Copyright © 2010 by AAN Enterprises, Inc.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

  • Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease
    • Kim A. Bruggink, Department of Neurology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsK.Bruggink@neuro.umcn.nl
    • H. Bea Kuiperij, Frida Ekholm-Pettersson (Uppsala University, Sweden), Marcel M. Verbeek Radboud University Nijmegen Medical Centre, The Netherlands
    Submitted February 17, 2011
  • Reply from the authors
    • Omar M. A. El-Agnaf, United Arab Emirates University, United Arab Emirates University, 17666 Al-Ain, United Arab Emirateso.elagnaf@uaeu.ac.ae
    • Takahiko Tokuda
    Submitted February 17, 2011
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias

Topics Discussed

  • Alzheimer's disease
  • Dementia with Lewy bodies
  • Parkinson's disease/Parkinsonism
  • Parkinson's disease with dementia
  • Tremor

Alert Me

  • Alert me when eletters are published
Neurology: 96 (8)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise